Fast path: latest quarter results by ticker or company name

Jenscare Scientific Co

9877.HK

HKD6.90 -3.77% Quote Jun 24, 8:08 AM

Exchange HKSE Sector Healthcare Industry Medical Specialties

Q4 2024

Reported

Published: Dec 31, 2024

Data: Financial Modeling Prep

Company Status Snapshot

Fast view of the latest quarter outcome for 9877.HK

Report Date

Dec 31, 2024

Quarter Q4 2024

Revenue

N/A

YoY: N/A

EPS

-0.09

YoY: +59.6%

Market Move

-3.77%

Previous quarter: Q3 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Net Income

-37.62K

YoY: +100.0%

N/A

— N/A

9877.HK

Company 9877.HK

Period Q4 2024

Currency CNY

Report Type Quarterly Earnings

Generated Jun 24, 2026

Swipe to view all report sections

Executive Summary

Summary of QQ4 2024 results and strategic context for Jenscare Scientific. The quarter shows a continuation of losses reflecting the company’s pre-commercial, R&D-intensive phase, with no disclosed revenue in the reported period. Despite the negative earnings, Jenscare carries a strong liquidity position and a substantial net cash footprint, providing ample runway to advance its lead product candidates, LuXValve (TTVR) and KenValve (TAVR), toward regulatory milestones and potential partnerships. The market backdrop for transcatheter valve therapies remains favorable, especially as China expands access to structural heart interventions, but execution risk remains high given clinical validation requirements and competitive dynamics.

Key Performance Indicators

Operating Income

Increasing

-46.65K

QoQ: 0.00% | YoY: 57.34%

Net Income

Increasing

-37.62K

QoQ: 0.00% | YoY: 99.96%

EPS

Increasing

-0.09

QoQ: 0.00% | YoY: 59.61%

Revenue Trend

Margin Analysis

Financial Highlights

Financial momentum and liquidity highlights (Q4 2024, CNY, year/quarter comparisons where available):
- Revenue: Not disclosed in the QQ4 2024 filing.
- EBITDA: -44,452,250.00
- Operating income: -46,648,000.00; QoQ: 0.00%; YoY: +57.34% (the magnitude of loss narrowed versus prior-year quarter).
- Net income: -37,624,500.00; QoQ: 0.00%; YoY: +99.96% (loss narrowed materially vs. prior-year quarter).
- Earnings per share (diluted): -0.0929 CNY; QoQ: 0.00%; YoY: +59.61%
- R&D expenses: 30,202,000.00
- General and administrative expenses: 16,446,000.00
- Depreciation & amortization: 2,195.75
- Cash and cash equivalents: 605,991,000.00
- Total assets: 1,027,565,000.00
- Total liabilities: 110,612,000.00
- Total stockholders’ equity: 931,762,000.00
- Net debt: -541,572,000.00 (net cash position)
- Current ratio: 10.68; Quick ratio: 10.13; Cash ratio: 9.44
- Weight avg shares out: 404,882,000; Weighted avg diluted: 404,879,000
- Price-to-book: 1.322; Price-to-earnings: negative (by reporting period)
- Return on assets (ROA): -0.0000366; Return on equity (ROE): -0.0000404

Income Statement

Metric	Value	YoY Change	QoQ Change
Operating Income	-46.65K	57.34%	0.00%
Net Income	-37.62K	99.96%	0.00%
EPS	-0.09	59.61%	0.00%

Key Financial Ratios

Return on Assets

Weak

0.00%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

0.00%

Return on equity suggests inefficient capital allocation

Current Ratio

Strong

10.68

Current ratio indicates excellent liquidity and financial flexibility

Debt to Equity

Conservative

0.07

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Negative

-8,186.55x

Negative earnings make P/E ratio not meaningful

Price to Book

Fair Value

1.32x

Price-to-book ratio reasonable for profitable companies

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q2 2025	6.71	-0.21	+0.0%	View
Q1 2025	0.00	-0.21	+0.0%	View
Q4 2024	0.00	-0.09	+0.0%	View
Q3 2024	0.00	-0.09	+0.0%	View

Source & Methodology

Data provider: Financial Modeling Prep (FMP). Figures are pulled directly from filed company reports.
Year-over-year (YoY): Each line is compared to the same fiscal quarter one year prior; figures sourced from the company's own filings.
Quote freshness: The price shown above the report is a live quote, separate from the as-filed report numbers. Live quotes can lag a few minutes.
Time zone: Report dates and timestamps follow the company's filing time zone unless otherwise noted.

Jenscare Scientific Co (9877.HK) Q4 2024 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Historical Earnings Comparison

More 9877.HK Quarterly Reports

9877.HK

9877.HK

9877.HK

Related Financial Data

Sector Analysis: Healthcare

9877.HK Full Profile

9877.HK Financial Statements

Earnings Calendar